# DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

> **NCT05882058** · PHASE2 · RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 204 (estimated)

## Conditions studied

- Small Cell Lung Carcinoma
- Neuroendocrine Neoplasms
- Extra-pulmonary Neuroendocrine Carcinoma

## Interventions

- **DRUG:** BI 764532, dose 1
- **DRUG:** BI 764532, dose 2

## Key facts

- **NCT ID:** NCT05882058
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-13
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-02-24
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05882058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05882058, "DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05882058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*